29/06/2026
A major review published in Carcinogenesis in just concluded that nicotine-based e-ci******es are likely carcinogenic to the lungs and oral cavity. What makes it worth understanding is not the conclusion. It is the method. The authors reached a carcinogenicity verdict without the one thing most people assume you need: human cancer data. For va**ng, that data does not exist yet, and by the authors' own account it will take decades to accumulate.
So they did what cancer science does when the bodies have not been counted. They assessed carcinogenicity from converging indirect evidence: biomarkers in people who v**e, tumor outcomes in animals, and the molecular behavior of the aerosol itself. The logic rests on a framework called the Key Characteristics of Carcinogens, a set of ten molecular properties shared by substances already known to cause cancer in humans, things like genotoxicity, oxidative stress, and chronic inflammation. The argument is that if a new exposure reproduces those same molecular hallmarks, you have a mechanistic basis to call it a probable carcinogen before the epidemiology arrives.
People who v**e carry roughly 100 times the cotinine of non-users, and biomarker studies link v**e-derived metabolites to measurable DNA damage in their tissue. In one rodent bioassay, 22.5 percent of mice breathing e-cigarette aerosol developed lung adenocarcinomas, against 1 of 40 controls. The aerosol carries established carcinogens: to***co-specific nitrosamines, volatile organic compounds, and metals shed from the heating coil. Across biomarker, animal, and mechanistic studies, the review argues the signals point the same direction.
The strongest human signal, though, comes with a caveat that matters enormously. The clearest cancer association so far is in dual users. A 2024 case-control study of 4,975 lung cancer patients found that people who both v**ed and smoked carried a fourfold higher lung cancer risk than people who only smoked. But 97 percent of the v**ers in that study also smoked to***co. That makes it nearly impossible to isolate what va**ng does on its own, which is the actual question. The dual-use finding is a warning about combined exposure, not evidence that va**ng alone causes cancer.
This is also where the review has drawn legitimate scientific criticism, and the criticism deserves airing rather than burial. Some epidemiologists have argued the review reaches beyond the evidence it presents, leaning on mechanistic plausibility to support a conclusion that human outcome data cannot yet support. They point out, fairly, that a separate 2025 systematic review making similar va**ng-cancer claims was retracted, and that this field has a pattern of conclusions running ahead of the data. The authors themselves are explicit that their assessment is qualitative and offers no numerical estimate of cancer risk or burden. So the honest state of play is this: the mechanistic and biomarker case is genuinely concerning and internally consistent, but it is not the same thing as a demonstrated human cancer risk, and reasonable scientists disagree about whether it is yet enough to call va**ng a carcinogen.
The molecular damage v**e aerosol does to human tissue is measurable right now. The cancer counts that would settle the question are the part that takes twenty years. The authors draw a deliberate parallel to to***co, where warning signs were dismissed for decades before the epidemiology caught up. Whether that parallel holds, or whether va**ng turns out to be meaningfully less carcinogenic than the mechanistic data suggests, is the open question. The "safer alternative" framing was always a comparison to ci******es, not a clean bill of health, and the gap between "less harmful than smoking" and "harmless" is exactly where this evidence sits.
Stewart et al., Carcinogenesis, 2026. Bittoni et al., J Oncol Res Ther, 2024. Smith et al., Environ Health Perspect, 2016. Sitas & Stewart, Cancer Epidemiology, 2026.
